Does estrogen replacement therapy protect against Alzheimer's disease?

Osteoporosis International

Volumn 7, Issue SUPPL. 1, 1997, Pages 12-17

  Paganini Hill, A ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CONJUGATED ESTROGEN; DIETHYLSTILBESTROL; ESTROGEN; ETHINYLESTRADIOL;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; CREAM; DEMENTIA; DRUG FORMULATION; DRUG MECHANISM; ESTROGEN THERAPY; FAMILY; FEMALE; HUMAN; INTRAVAGINAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS;

EID: 0030945401     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf01674807     Document Type: Conference Paper

References (61)

1. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987;76.465-79.
2. Evans DA, Funkenstein H, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 1989;262:2551-6.
3. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited Am J Public Health 1994;84:1261-4.
4. Breteler MMB, Claus JJ, van Duijn CM, et al. Epidemiology of Alzheimer's disease. Epidemiol Rev 1992;14:59-82.
5. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sci USA 1993;90:1977-81.
6. Heyman A, Wilkinson WE, Stafford JA, et al. Alzheimer's disease: a study of epidemiological aspects. Ann Neurol 1984;15:335-41.
7. Amaducci LA, Fratiglioni L, Rocca WA, et al. Risk factors for clinically diagnosed Alzheimer's disease: a case-control study of an Italian population. Neurology 1986;36:922-31.
8. Broe GA, Henderson AS, Creasey H, et al. A case-control study of Alzheimer's disease in Australia. Neurology 1990;40:1698-707.
9. Graves AB, White E, Koepsell TD, et al. A case-control study of Alzheimer's disease. Ann Neurol 1990;28:766-74.
10. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA 1993;269:2637-41.
11. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994;140:256-61.
12. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer's disease. Arch Intern Med 1996;156:2213-7.
13. Brenner DE, Kukull WA, Stergachis A, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol 1994;140:262-7.
14. Henderson VW, Paganini-Hill A, Emanuel CK, et al. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 1994;51:896-900.
15. Mortel KF, Meyer JS. Lack of postmenopausal estrogen replacement therapy and the risk of dementia. J Neuropsychiatry Clin Neurosci 1995;7:334-7.
16. Lerner A, Cole R, Debanne S, et al. Immunological and endocrine conditions in an Alzheimer's disease case-control study [abstract]. Neuroepidemiology 1995;14:307.
17. Morrison A, Resnick S, Corrada M, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease in the Baltimore Longitudinal Study of Aging [abstract]. Neurology 1996;46:A435-6.
18. Tang M-X, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-32.
19. Fillit H, Weinreb H, Cholst I, et al. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology 1986;11:337-45.
20. Weiss BL. Failure of nalmefene and estrogen to improve memory in Alzheimer's disease. Am J Psychiatry 1987;144:386-7.
21. Honjo H, Ogino Y, Naitoh K, et al. In vivo effects by estrone sulfate on the central nervous system: senile dementia (Alzheimer's type). J Steroid Biochem 1989;34:521-5.
22. Honjo H, Ogino Y, Tanaka K, et al. An effect of conjugated estrogen to cognitive impairment in women with senile dementia-Alzheimer's type: a placebo-controlled double blind study. J Jpn Menopause Soc 1993;1:167-71.
23. Ohkura T, Isse K, Akazawa K, et al. Evaluation of estrogen therapy in female patients with dementia of the Alzheimer type. Endocr J 1994;41:361-71.
24. Ohkura T, Isse K, Akazawa K, et al. Low-dose estrogen replacement therapy for Alzheimer disease in women. Menopause 1994;1:125-30.
25. Honjo H, Tanaka K, Kashiwagi T, et al. Senile dementia-Alzheimer's type and estrogen. Horm Metab Res 1995;27:204-7.
26. Ohkura T, Isse K, Akazawa K, et al. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports. Dementia 1995;6:99-107.
27. Luine VN. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol 1985;89:484-90.
28. Toran-Allerand CD, Miranda RC, Bentham WDL, et al. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci USA 1992;89:4668-72.
29. Singh M, Meyer EM, Millard WJ, Simpkins JW. Ovarian steroid deprivation results in a reversal learning impairment and compromised cholinergic function in female Sprague-Dawley rats. Brain Res 1994;644:305-12.
30. 3H-oestradiol. Nature 1981;289:500-2.
31. Cohen IR, Wise PM. Effects of estradiol on the diurnal rhythm of serotonin activity in microdissected brain areas of ovariectomized rats. Endocrinology 1988;122:2619-25.
32. Thompson TL, Moss RL. Estrogen regulation of dopamine release in the nucleus accumbens: genomic- and nongenomic-mediated effects. J Neurochem 1994;62:1750-6.
33. Weiland NG. Estradiol selectively regulates agonist binding sites on the N-methyl-D-aspanate receptor complex in the CA1 region of the hippocampus. Endocrinology 1992;131:662-8.
34. Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217:408-17.
35. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983;219:1184-90.
36. Kaufman H, Vadasz C, Lajtha A. Effects of estradiol and dexamethasone on choline acetyltransferase activity in various rat brain regions. Brain Res 1988;453:389-92.
37. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-91.
38. Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996;46:1580-4.
39. Matsumoto A. Synaptogenic action of sex steroids in developing and adult neuroendocrine brain. Psychoneuroendocrinology 1991;16:25-40.
40. Chung SK, Pfaff DW, Cohen RS. Estrogen-induced alterations in synaptic morphology in the midbrain central gray. Exp Brain Res 1988;69:522-30.
41. Naftolin F, Leranth C, Perez J, Garcia-Segura LM. Estrogen induces synaptic plasticity in adult primate neurons. Neuroendocrinology 1993;57:935-9.
42. Jones KJ. Steroid hormones and neurotrophism: relationship to nerve injury. Metab Brain Dis 1988;3:1-18.
43. Sohrabji F, Miranda RC, Toran-Allerand CD. Estrogen differentially regulates estrogen and nerve growth factor receptor mRNAs in adult sensory neurons. J Neurosci 1994;14:459-71.
44. Hyman BT, van Hoesen GW, Damasio AR, Barnes CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 1984;225:1168-70.
45. Gould E, Woolley CS, Frankfurt M, McEwen BS. Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood. J Neurosci 1990;10:1286-91.
46. Wong M, Moss RL. Long-term and short-term electrophysiological effects of estrogen on the synaptic properties of hippocampal CA1 neurons. J Neurosci 1992;12:3217-25.
47. Jaffe AB, Toran-Allerand CD, Greengard P, Gandy SE. Estrogen regulates metabolism of Alzheimer amyloid β precursor protein. J Biol Chem 1994;269:13065-8.
48. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid β protein toxicity. Cell 1994;77:817-27.
49. Sagara Y, Dargusch R, Kleir FG, et al. Increased antioxidant enzyme activity in amyloid β protein-resistant cells. J Neurosci 1996;16:497-505.
50. Niki E, Nakano M. Estrogens as antioxidants. Method Enzymol 1990;186:330-3.
51. Mooradian AD. Antioxidant properties of steroids. J Steroid Biochem Mol Biol 1993;45:509-11.
52. Peacock ML, Fink JK. ApoE ∈4 allelic association with Alzheimer's disease: independent confirmation using denaturing gradient gel electrophoresis. Neurology 1994;44:339-41.
53. Hardy J. ApoE, amyloid and Alzheimer's disease. Science 1994;263:454-5.
54. Applebaum-Bowden D, McLean P, Steinmetz A, et al. Lipoprotein, apolipoprotein, and lipolytic enzyme changes following estrogen administration in postmenopausal women. J Lipid Res 1989;30:1895-906.
55. McGreer PL, McGreer EG. The inflammatory response system of brain: implications for therapy of Atzheimer and other neurodegenerative diseases. Brain Res Rev 1995;21:195-218.
56. Bauer J, Ganter U, Strauss S, et al. The participation of interleukin-6 in the pathogenesis of Alzheimer's disease. Res Immunol 1992;143:650-7.
57. Ershler WB. Interleukin-6: a cytokine for gerontologists. J Am Geriatr Soc 1993;41:176-81.
58. Manning C, Ragozzino ME, Gold PE. Glucose enhancement of memory in patients with probable senile dementia of the Alzheimer's type. Neurobiol Aging 1993;14:523-8.
59. Bishop J, Simpkins JW. Role of estrogens in peripheral and cerebral glucose utilization. Rev Neurosci 1992;3:121-37.
60. Belfort MA, Saade GR, Snabes M, et al. Hormonal status affects the reactivity of the cerebral vasculature. Am J Obstet Gynecol 1995;172:1273-8.
61. Breitner JCS. Clinical genetics and genetic counseling in Alzheimer's disease. Ann Intern Med 1991;115:601-6.